SkinBioTherapeutics will "continue to be flexible enough to adapt to opportunities" | News Direct

SkinBioTherapeutics will "continue to be flexible enough to adapt to opportunities"

SkinBioTherapeutics PLC
Digital Asset Direct by SkinBioTherapeutics PLC

facebook icon linkedin icon twitter icon pinterest icon email icon London, UK | December 19, 2022 06:14 AM Eastern Standard Time

SkinBioTherapeutics PLC (AIM:SBTX) chief executive Stuart Ashman speaks to Proactive after announcing the raising of £2.5mln via a placing of new shares. He reveals what the company intends to do with the new funding, that may be augmented by a further £1mln from a retail offer. Ashman says that SkinBioTherapeutics "has always been and always will continue to be flexible enough to adapt to opportunities as and when they come [its] way."

 

Contact Details

 

Proactive

 

Proactive UK Ltd

 

+44 20 7989 0813

 

uk@proactiveinvestors.com